Announced Sun, 12 Oct · 13:07 IST

Compliance 57(4) as on 30th September 2025

Compliance View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+2.6%1-day move

₹4.16

prior close

₹4.16

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.0+4.6+4.6+2.9+2.6+2.2+3.1+3.6+2.9+1.9-11.5-6.0-34.6-35.3

Up moveDown movePending

AI summary

Transgene Biotek has submitted its quarterly compliance under SEBI's Regulation 57 for the period ended September 30, 2025. The company informed BSE that this regulation does not apply to it because it does not have any non-convertible securities with interest, dividend, or principal payments due during the quarter. The letter was signed by Dr. K. Koteswara Rao, Chairman and Managing Director. This is a routine regulatory filing rather than a substantive corporate action.

Likely market impact

No material impact on shareholders or stock price — this is a routine non-applicability disclosure confirming the company has no outstanding non-convertible debt obligations requiring disclosure.